fluoxetine and Acathisia, Drug-Induced studies

Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.

Research Excerpts

Excerpt	Relevance	Reference
"The efficacy and safety of fluoxetine, a new antidepressant agent, were assessed in a double-blind, parallel, randomized study of 44 outpatients with major depressive disorder."	9.05	A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. ( Feighner, JP, 1985)
" We present the case of a young man who developed an acute akathisia and dystonia after inadvertent overdose of olanzapine (Zyprexa) in the setting of a recent discontinuation of fluoxetine."	7.73	Acute olanzapine-induced akathisia and dystonia in a patient discontinued from fluoxetine. ( Dufel, S; Paige, T; Vena, J, 2006)
"A 48-year-old man presented to the emergency department with confusion, agitation, diaphoresis, and muscle rigidity after beginning treatment with fluoxetine, a serotonin reuptake inhibitor."	7.69	Fluoxetine and the serotonin syndrome. ( Ruiz, F, 1994)
" To assess rates and temporal patterns of activation and sedation as well as dose-effect relationships, adverse event data were evaluated from a fixed-dose study comparing placebo and fluoxetine 5, 20, and 40 mg/day in the treatment of major depressive disorder (N = 363) and two fixed-dose studies pooled together comparing placebo and fluoxetine 20, 40, and 60 mg/day in the treatment of major depressive disorder (N = 746)."	5.07	Fluoxetine: activating and sedating effects at multiple fixed doses. ( Beasley, CM; Potvin, JH; Sayler, ME; Weiss, AM, 1992)
" For individual adverse events that developed or worsened during therapy, more fluoxetine-treated patients reported rhinitis and tremor (p less than or equal to ."	5.07	Fluoxetine versus trazodone: efficacy and activating-sedating effects. ( Beasley, CM; Bosomworth, JC; Dornseif, BE; Pultz, JA; Sayler, ME, 1991)
"The effect of dose frequency on fluoxetine efficacy and safety was evaluated in a double-blind study in patients with major depressive disorder."	5.05	Comparison of two dosage regimens of fluoxetine in major depression. ( Amsterdam, JB; Glaudin, V; Rickels, K; Settle, GP; Smith, WT; Weise, C, 1985)
"The efficacy and safety of fluoxetine, a new antidepressant agent, were assessed in a double-blind, parallel, randomized study of 44 outpatients with major depressive disorder."	5.05	A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. ( Feighner, JP, 1985)
"The side effect profile and safety of fluoxetine are reviewed."	3.75	The side effect profile and safety of fluoxetine. ( Wernicke, JF, 1985)
" We present the case of a young man who developed an acute akathisia and dystonia after inadvertent overdose of olanzapine (Zyprexa) in the setting of a recent discontinuation of fluoxetine."	3.73	Acute olanzapine-induced akathisia and dystonia in a patient discontinued from fluoxetine. ( Dufel, S; Paige, T; Vena, J, 2006)
"A 48-year-old man presented to the emergency department with confusion, agitation, diaphoresis, and muscle rigidity after beginning treatment with fluoxetine, a serotonin reuptake inhibitor."	3.69	Fluoxetine and the serotonin syndrome. ( Ruiz, F, 1994)
"Aripiprazole is an effective and safe adjunctive therapy as demonstrated in this short-term study for patients who are nonresponsive to standard ADT."	2.73	The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. ( Berman, RM; Carson, WH; Fava, M; Hennicken, D; Marcus, RN; McQuade, RD; Simon, JS; Thase, ME; Trivedi, MH, 2008)
"or fluoxetine p."	2.67	Efficacy and safety of morning versus evening fluoxetine administration. ( Beasley, CM; Bosomworth, JC; Usher, RW, 1991)
"Fluoxetine was superior to placebo in treating suicidal ideation, and the concomitant use of sedatives did not influence this effect."	2.40	Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: the absence of an effect related to agitation and suicidal behavior. ( Koke, SC; Pearson, DK; Sayler, ME; Tollefson, GD; Wernicke, JF, 1997)
"Patients who developed dystonia, parkinsonism, or tardive dyskinesia were older on average than patients with akathisia; 67."	2.39	Movement disorders associated with the serotonin selective reuptake inhibitors. ( Leo, RJ, 1996)
" The patient developed severe restlessness and de novo suicidal ideation approximately 1 week after the dosage of fluoxetine was doubled, 1 year on from when the drug was first introduced."	1.32	Fluoxetine dose-increment related akathisia in depression: implications for clinical care, recognition and management of selective serotonin reuptake inhibitor-induced akathisia. ( Hansen, L, 2003)
"All three patients developed severe akathisia during retreatment with fluoxetine and stated that the development of the akathisia made them feel suicidal and that it had precipitated their prior suicide attempts."	1.28	Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. ( Locke, CA; Rothschild, AJ, 1991)
" In general, fluoxetine, which was administered from 4 to 20 weeks at a dosage of 10 or 40 mg per day, was well tolerated."	1.28	Fluoxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorders: preliminary clinical experience. ( Hardin, MT; King, R; Riddle, MA; Scahill, L; Woolston, JL, 1990)

Research

Studies (50)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

MADRS (Montgomery-Asberg Depression Rating Scale) Readmission Rate

Timeframe	Studies, this research(%)	All Research%
pre-1990	6 (12.00)	18.7374
1990's	35 (70.00)	18.2507
2000's	7 (14.00)	29.6817
2010's	2 (4.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Philip, NS	1
Sabaawi, M	1
Holmes, TF	1
Fragala, MR	1
Saddichha, S	1
Kumar, R	1
Babu, GN	1
Chandra, P	1
Hansen, L	1
Vena, J	1
Dufel, S	1
Paige, T	1
Menza, MA	1
Dobkin, RD	1
Marin, H	1
Back, I	1
Taubert, M	1
Marcus, RN	1
McQuade, RD	1
Carson, WH	1
Hennicken, D	1
Fava, M	1
Simon, JS	1
Trivedi, MH	1
Thase, ME	1
Berman, RM	1
Marshall, RD	1
Printz, D	1
Cardenas, D	1
Abbate, L	1
Liebowitz, MR	1
D'Souza, DC	1
Bennett, A	1
Abi-Dargham, A	1
Krystal, JH	1
Tollefson, GD	2
Greist, JH	1
Jefferson, JW	1
Heiligenstein, JH	1
Sayler, ME	4
Tollefson, SL	1
Koback, K	1
Amsterdam, JD	1
Hornig-Rohan, M	1
Maislin, G	1
Stoll, AL	1
Mayer, PV	1
Kolbrener, M	1
Goldstein, E	1
Suplit, B	1
Lucier, J	1
Cohen, BM	1
Tohen, M	1
Ruiz, F	1
Kalda, R	1
Gupta, S	1
Ketai, R	1
Bostwick, JM	1
Brown, TM	1
Levy, F	1
Einfeld, S	1
Looi, J	1
Teicher, MH	1
Klein, DA	1
Andersen, SL	1
Wallace, P	1
Leo, RJ	1
Bauer, M	1
Hellweg, R	1
Baumgartner, A	1
Scahill, L	2
Riddle, MA	2
King, RA	1
Hardin, MT	2
Rasmusson, A	1
Makuch, RW	1
Leckman, JF	1
Wernicke, JF	2
Koke, SC	1
Pearson, DK	1
Arya, DK	1
Benazzi, F	1
Chelben, J	1
Strous, RD	1
Lustig, M	1
Baruch, Y	1
Akagi, H	1
Kumar, TM	1
Hamilton, MS	1
Opler, LA	1
Beasley, CM	3
Weiss, AM	1
Potvin, JH	1
Wirshing, WC	1
Van Putten, T	1
Rosenberg, J	1
Marder, S	1
Ames, D	1
Hicks-Gray, T	1
Pearlman, T	1
Rothschild, AJ	1
Locke, CA	1
Fleischhacker, WW	1
Usher, RW	1
Bosomworth, JC	2
Dornseif, BE	1
Pultz, JA	1
Metz, A	1
King, R	1
Woolston, JL	1
Giesecke, ME	1
Maany, I	1
Dhopesh, V	1
Feighner, JP	2
Boyer, WF	1
Tyler, DL	1
Neborsky, RJ	1
Friedman, EH	2
Lipinski, JF	1
Mallya, G	1
Zimmerman, P	1
Pope, HG	1
Steiner, W	1
Fontaine, R	1
Rickels, K	1
Smith, WT	1
Glaudin, V	1
Amsterdam, JB	1
Weise, C	1
Settle, GP	1
Stark, P	1
Hardison, CD	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder[NCT00095758]	Phase 3	1,200 participants	Interventional	2004-09-30	Completed
A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy (ADT) Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior ADT[NCT00683852]	Phase 3	225 participants (Actual)	Interventional	2008-09-30	Completed
Transcranial Magnetic Stimulation for Individuals With Tourette's Syndrome[NCT00529308]	Phase 2	20 participants (Actual)	Interventional	2007-07-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

MADRS readmission rate is defined as MADRS score<11. The 10-item Montgomery-Asberg Depression Rating Scale (MADRS), which measures depression severity over the past week, was completed by clinicians using an MGH structured interview. Each item is measured on a scale from 0 to 6, and the items are summed to find the total score. The total minimum score is 0 units on a scale and the total maximum score is 60 units on a scale, where higher scores indicate more severe depression. (NCT00683852)
Timeframe: 12 weeks

MADRS (Montgomery-Asberg Depression Rating Scale) Response Rate

Intervention	Participants (Count of Participants)
Phase 1 Drug	4
Phase 1 Placebo Non-Responders on Drug in Phase 2	8
Phase I Placebo	16
Phase 1 Placebo Non-Responders on Placebo in Phase 2	4

The primary outcome was the difference in response rate (decrease in MADRS total score of at least 50%) using the SPCD (sequential parallel comparison design). The 10-item Montgomery-Asberg Depression Rating Scale (MADRS), which measures depression severity over the past week, was completed by clinicians using an MGH structured interview. Each item is measured on a scale from 0 to 6, and the items are summed to find the total score. The total minimum score is 0 units on a scale and the total maximum score is 60 units on a scale, where higher scores indicate more severe depression. (NCT00683852)
Timeframe: 12 weeks

Mean Change in Clinical Global Impression of Severity (CGI-S)

Intervention	Participants (Count of Participants)
Phase 1 Drug	10
Phase 1 Placebo Non-Responders on Drug in Phase 2	11
Phase I Placebo	29
Phase 1 Placebo Non-Responders on Placebo in Phase 2	5

The CGI-S scale was administered by clinicians based on assessment of the patient's clinical status. They measured, based on history and scores on other instruments, depressive severity. It consists of one question scored on a seven-point scale (1 = normal to 7 = among the most severe), so a higher total score indicates greater depressive severity. The minimum score is 1, and the maximum score is 7. (NCT00683852)
Timeframe: Baseline and 12 weeks

Mean Change in MADRS (Montgomery-Asberg Depression Rating Scale) Score From Baseline to the End of Follow-up

Intervention	units on a scale (Mean)
Phase 1 Drug	-0.81
Phase 1 Placebo Non-Responders on Drug in Phase 2	-0.64
Phase I Placebo	-0.84
Phase 1 Placebo Non-Responders on Placebo in Phase 2	-0.43

The 10-item Montgomery-Asberg Depression Rating Scale (MADRS), which measures depression severity over the past week, was completed by clinicians using an MGH structured interview. Each item is measured on a scale from 0 to 6, and the items are summed to find the total score. The total minimum score is 0 units on a scale and the total maximum score is 60 units on a scale, where higher scores indicate more severe depression. (NCT00683852)
Timeframe: Baseline and 12 Weeks

Number of Patients With Treatment Emergent AEs in Two Treatment Groups - People Exclusively on Drug or Placebo Throughout the Study

Intervention	units on a scale (Mean)
Phase 1 Drug	-8.54
Phase 1 Placebo Non-Responders on Drug in Phase 2	-5.80
Phase I Placebo	-8.09
Phase 1 Placebo Non-Responders on Placebo in Phase 2	-3.32

Differences in the incidence of treatment emergent AEs between the treatment groups were examined and evaluated using descriptive statistics. This analysis compared AEs between the arms that received exclusively drug throughout the study or placebo throughout the study. (NCT00683852)
Timeframe: 12 Weeks

Number of Patients With Treatment Emergent AEs in Two Treatment Groups - Placebo Non-Responders

Intervention	Patients (Number)
ADAPT Drug/Drug Group	39
ADAPT Placebo/Placebo Group	60

Differences in the incidence of treatment emergent AEs between the treatment groups were examined and evaluated using descriptive statistics. This analysis focused on placebo non-responders in phase 1 and presented them by their treatment assignment in phase 2. (NCT00683852)
Timeframe: 12 Weeks

Treatment Emergent AEs in Two Treatment Groups - Safety Sample

Intervention	Patients (Number)
Phase 1 Placebo Non-Responders on Drug in Phase 2	40
Phase 1 Placebo Non-Responders on Placebo in Phase 2	44

Differences in the incidence of treatment emergent AEs between the treatment groups were examined and evaluated using descriptive statistics. In this analysis, AEs were summarized according to person-phase of occurrence. Each AE was attributed to the person and then to phase 1 or phase 2, depending on the initial date of onset. (NCT00683852)
Timeframe: 12 Weeks

Mean Change in Symptom Questionnaire (SQ)

Intervention	adverse events (Number)
ADAPT Drug Group	58
ADAPT Placebo Group	110

The SQ, a 92-item (yes/no) self-rating questionnaire, includes 4 distress and 4 well-being subscales. There are 68 items for the distress subscales and 24 items for the well-being subscales. Each item has either a Yes/No or True/False answer. For the distress symptom score, add together the following items and score 1 when the answer is Yes/True: 1, 2, 3, 5, 6, 8, 11, 12, 15, 18, 20, 22, 24, 25, 26, 27, 28, 29, 30, 32, 33, 34, 36, 37, 39, 41, 42, 44, 45, 47, 48, 49, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 72, 73, 74, 75, 76, 77, 79, 80, 81, 82, 84, 85, 86, 87, 88, 90, 91, 92. Minimum score is 0 and maximum score is 68. A higher score indicates more distress symptoms. For the well-being subscale score, add together the following items and score 1 when the answer is No/False: 4, 7, 9, 10, 13, 14, 16, 17, 19, 21, 23, 29, 31, 35, 38, 40, 43, 46, 50, 51, 71, 78, 83, 89. Minimum score is 0 and maximum score is 24. A higher score indicates more well-being. (NCT00683852)
Timeframe: Baseline and 12 weeks

"Number of Patients With Improved or Minimally Improved in Clinical Global Impression-Improvement (CGI) Scale"

Intervention	units on a scale (Mean)
	Sum of 4 subscaled distress scores	Sum of 4 subscaled well-being scores
Phase 1 Drug	-9.44	3.71
Phase 1 Placebo Non-Responders on Drug in Phase 2	-6.78	3.34
Phase 1 Placebo Non-Responders on Placebo in Phase 2	-4.52	1.98
Phase I Placebo	-9.70	2.75

"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks

"Number of Patients With Much Improved or Very Much Improved on Clinical Global Impression-Improvement (CGI) Scale"

Intervention	participants (Number)
Active	2
Sham	8

Motor Cortex Excitability Normalization-Left Motor Threshold

Intervention	participants (Number)
Active	1
Sham	0

Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks

Motor Cortex Excitability Normalization-Right Motor Threshold

Intervention	µV (Mean)
Active	56.5
Sham	63.8

Yale Global Tic Severity Scale (Y-GTSS)

Intervention	µV (Mean)
Active	56
Sham	59.8

Y-GTSS is a clinician-rated scale used to assess tic severity. Motor and phonic tics are rated separately from 0 to 5 on several scales including number, frequency, intensity, complexity, and interference. Thus Motor and Phonic Tic scores can range from 0 to 25; the combined Total Tic Score ranges from 0 to 50. There is also an Impairment score that rates the overall burden due to tics. The Impairment scale yields a single score from 0 to 50 with higher scores indicating higher levels of overall impairment associated with tics. (NCT00529308)
Timeframe: 3 weeks

Article	Year
Drug-induced akathisia: subjective experience and objective findings. Military medicine, 1994, Volume: 159, Issue:4 Topics: Akathisia, Drug-Induced; Animals; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents;	1994
Movement disorders associated with the serotonin selective reuptake inhibitors. The Journal of clinical psychiatry, 1996, Volume: 57, Issue:10 Topics: 1-Naphthylamine; Adult; Age Factors; Aged; Akathisia, Drug-Induced; Depressive Disorder; Dyskinesia,	1996
Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: the absence of an effect related to agitation and suicidal behavior. Depression and anxiety, 1997, Volume: 6, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Akathisia, Drug-Induced; Anti-Anxiety Agents; Antidepres	1997
Akathisia, suicidality, and fluoxetine. The Journal of clinical psychiatry, 1992, Volume: 53, Issue:11 Topics: Akathisia, Drug-Induced; Basal Ganglia Diseases; Depression; Fluoxetine; Humans; Models, Neurologica	1992
The side effect profile and safety of fluoxetine. The Journal of clinical psychiatry, 1985, Volume: 46, Issue:3 Pt 2 Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Tricyclic; Cardiovascular Diseases; Clinical	1985

Article	Year
An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder. Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:2 Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Antipsyc	2007
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:2 Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Citalopram; Cyclohexanols; Depr	2008
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:2 Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Citalopram; Cyclohexanols; Depr	2008
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:2 Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Citalopram; Cyclohexanols; Depr	2008
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:2 Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Citalopram; Cyclohexanols; Depr	2008
Adverse events in PTSD patients taking fluoxetine. The American journal of psychiatry, 1995, Volume: 152, Issue:8 Topics: Akathisia, Drug-Induced; Arousal; Fluoxetine; Humans; Panic Disorder; Prospective Studies; Single-Bl	1995
Is baseline agitation a relative contraindication for a selective serotonin reuptake inhibitor: a comparative trial of fluoxetine versus imipramine. Journal of clinical psychopharmacology, 1994, Volume: 14, Issue:6 Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Contraindications; Depressive Disorder; Double-Bli	1994
Fluoxetine has no marked effect on tic symptoms in patients with Tourette's syndrome: a double-blind placebo-controlled study. Journal of child and adolescent psychopharmacology, 1997,Summer, Volume: 7, Issue:2 Topics: Adolescent; Adult; Akathisia, Drug-Induced; Child; Cross-Over Studies; Double-Blind Method; Female;	1997
Fluoxetine: activating and sedating effects at multiple fixed doses. Journal of clinical psychopharmacology, 1992, Volume: 12, Issue:5 Topics: Adult; Akathisia, Drug-Induced; Ambulatory Care; Anxiety; Asthenia; Depressive Disorder; Dose-Respon	1992
Efficacy and safety of morning versus evening fluoxetine administration. The Journal of clinical psychiatry, 1991, Volume: 52, Issue:3 Topics: Adolescent; Adult; Akathisia, Drug-Induced; Circadian Rhythm; Depressive Disorder; Double-Blind Meth	1991
Fluoxetine versus trazodone: efficacy and activating-sedating effects. The Journal of clinical psychiatry, 1991, Volume: 52, Issue:7 Topics: Adult; Akathisia, Drug-Induced; Ambulatory Care; Anxiety; Depressive Disorder; Dizziness; Double-Bli	1991
The side effect profile and safety of fluoxetine. The Journal of clinical psychiatry, 1985, Volume: 46, Issue:3 Pt 2 Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Tricyclic; Cardiovascular Diseases; Clinical	1985
Comparison of two dosage regimens of fluoxetine in major depression. The Journal of clinical psychiatry, 1985, Volume: 46, Issue:3 Pt 2 Topics: Adult; Akathisia, Drug-Induced; Anxiety; Clinical Trials as Topic; Depressive Disorder; Dose-Respons	1985
A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder. The Journal of clinical psychiatry, 1985, Volume: 46, Issue:3 Pt 2 Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Ambulatory Care; Anxiety; Clinical Trials as Topic	1985
A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. The Journal of clinical psychiatry, 1985, Volume: 46, Issue:9 Topics: Adult; Aged; Akathisia, Drug-Induced; Ambulatory Care; Amitriptyline; Clinical Trials as Topic; Depr	1985

Article	Year
An aripiprazole discontinuation syndrome. Rhode Island medical journal (2013), 2013, Volume: 96, Issue:2 Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressiv	2013
Aripiprazole associated with acute dystonia, akathisia, and parkinsonism in a single patient. Journal of clinical pharmacology, 2012, Volume: 52, Issue:9 Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Arip	2012
Fluoxetine dose-increment related akathisia in depression: implications for clinical care, recognition and management of selective serotonin reuptake inhibitor-induced akathisia. Journal of psychopharmacology (Oxford, England), 2003, Volume: 17, Issue:4 Topics: Adult; Akathisia, Drug-Induced; Depressive Disorder; Dose-Response Relationship, Drug; Female; Fluox	2003
Acute olanzapine-induced akathisia and dystonia in a patient discontinued from fluoxetine. The Journal of emergency medicine, 2006, Volume: 30, Issue:3 Topics: Accidents; Acute Disease; Adult; Akathisia, Drug-Induced; Benzodiazepines; Drug Overdose; Dystonia;	2006
Akathisia and an unusual symptomatic treatment: a case report. Palliative medicine, 2007, Volume: 21, Issue:8 Topics: Akathisia, Drug-Induced; Cyclizine; Exercise Therapy; Female; Fluoxetine; Haloperidol; Humans; Metho	2007
Precipitation of a psychoneuromotor syndrome by fluoxetine in a haloperidol-treated schizophrenic patient. Journal of clinical psychopharmacology, 1994, Volume: 14, Issue:5 Topics: Akathisia, Drug-Induced; Drug Therapy, Combination; Fluoxetine; Haloperidol; Humans; Male; Middle Ag	1994
Artificial paradise encapsulated. Lancet (London, England), 1994, Apr-09, Volume: 343, Issue:8902 Topics: Akathisia, Drug-Induced; Fluoxetine; Humans; Suicide	1994
Efficacy of alprazolam in reducing fluoxetine-induced jitteriness in patients with major depression. The Journal of clinical psychiatry, 1994, Volume: 55, Issue:9 Topics: Adult; Akathisia, Drug-Induced; Alprazolam; Ambulatory Care; Depressive Disorder; Drug Therapy, Comb	1994
Antidepressant-associated mania: a controlled comparison with spontaneous mania. The American journal of psychiatry, 1994, Volume: 151, Issue:11 Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Antidepressive Agents, Tricyclic; Bipolar Dis	1994
Fluoxetine and the serotonin syndrome. Annals of emergency medicine, 1994, Volume: 24, Issue:5 Topics: Akathisia, Drug-Induced; Confusion; Drug Therapy, Combination; Emergency Medicine; Fluoxetine; Human	1994
Media- or fluoxetine-induced akathisia? The American journal of psychiatry, 1993, Volume: 150, Issue:3 Topics: Akathisia, Drug-Induced; Fluoxetine; Humans; Mass Media; Patient Compliance; Suicide	1993
Media- or fluoxetine-induced akathisia? The American journal of psychiatry, 1993, Volume: 150, Issue:3 Topics: Akathisia, Drug-Induced; Fluoxetine; Humans; Mass Media; Patient Compliance; Suicide	1993
Interaction between fluoxetine and neuroleptics. The American journal of psychiatry, 1993, Volume: 150, Issue:5 Topics: Akathisia, Drug-Induced; Basal Ganglia Diseases; Drug Interactions; Fluoxetine; Fluphenazine; Humans	1993
A toxic reaction from combining fluoxetine and phentermine. Journal of clinical psychopharmacology, 1996, Volume: 16, Issue:2 Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Appetite Depressants; Arou	1996
Combined pharmacotherapy or polypharmacy? Journal of paediatrics and child health, 1996, Volume: 32, Issue:3 Topics: Aggression; Akathisia, Drug-Induced; Amitriptyline; Antidepressive Agents, Tricyclic; Attention Defi	1996
Development of an animal model of fluoxetine akathisia. Progress in neuro-psychopharmacology & biological psychiatry, 1995, Volume: 19, Issue:8 Topics: Akathisia, Drug-Induced; Animals; Central Nervous System Stimulants; Dextroamphetamine; Dose-Respons	1995
Fluoxetine-induced akathisia does not reappear after switch to paroxetine. The Journal of clinical psychiatry, 1996, Volume: 57, Issue:12 Topics: Akathisia, Drug-Induced; Depressive Disorder; Female; Fluoxetine; Hospitalization; Humans; Middle Ag	1996
Existing brain condition may predispose to SSRI-induced extrapyramidal symptoms. The Australian and New Zealand journal of psychiatry, 1997, Volume: 31, Issue:5 Topics: Akathisia, Drug-Induced; Basal Ganglia Diseases; Bipolar Disorder; Cerebral Infarction; Female; Fluo	1997
SSRI discontinuation syndrome treated with fluoxetine. International journal of geriatric psychiatry, 1998, Volume: 13, Issue:6 Topics: Aged; Akathisia, Drug-Induced; Dizziness; Drug Administration Schedule; Female; Fluoxetine; Humans;	1998
Remission of SSRI-induced akathisia after switch to nefazodone. The Journal of clinical psychiatry, 2001, Volume: 62, Issue:7 Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Depressive Disorder; Drug	2001
Lesson of the week: Akathisia: overlooked at a cost. BMJ (Clinical research ed.), 2002, Jun-22, Volume: 324, Issue:7352 Topics: Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Antiemetics; Female; Fluoxetine;	2002
Fluoxetine, akathisia, and suicidality: is there a causal connection? Archives of general psychiatry, 1992, Volume: 49, Issue:7 Topics: Adult; Akathisia, Drug-Induced; Depressive Disorder; Female; Fluoxetine; Humans; Middle Aged; Psycho	1992
Fluoxetine and suicidality. The Journal of clinical psychiatry, 1992, Volume: 53, Issue:7 Topics: Akathisia, Drug-Induced; Anxiety Disorders; Basal Ganglia Diseases; Depressive Disorder; Dose-Respon	1992
Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. The Journal of clinical psychiatry, 1991, Volume: 52, Issue:12 Topics: Adult; Akathisia, Drug-Induced; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine;	1991
Propanolol for fluoxetine-induced akathisia. Biological psychiatry, 1991, Sep-01, Volume: 30, Issue:5 Topics: Akathisia, Drug-Induced; Depressive Disorder; Female; Fluoxetine; Humans; Middle Aged; Neurologic Ex	1991
Interaction between fluoxetine and buspirone. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1990, Volume: 35, Issue:8 Topics: Adult; Akathisia, Drug-Induced; Anxiety Disorders; Buspirone; Depressive Disorder; Drug Therapy, Com	1990
Fluoxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorders: preliminary clinical experience. Journal of the American Academy of Child and Adolescent Psychiatry, 1990, Volume: 29, Issue:1 Topics: Adolescent; Akathisia, Drug-Induced; Child; Female; Fluoxetine; Humans; Male; Obsessive-Compulsive D	1990
Overcoming hypersensitivity to fluoxetine in a patient with panic disorder. The American journal of psychiatry, 1990, Volume: 147, Issue:4 Topics: Adult; Akathisia, Drug-Induced; Anxiety Disorders; Drug Administration Schedule; Fear; Fluoxetine; H	1990
Akathisia and fluoxetine. The Journal of clinical psychiatry, 1990, Volume: 51, Issue:5 Topics: Akathisia, Drug-Induced; Dose-Response Relationship, Drug; Fluoxetine; Humans; Research Design; Rest	1990
Adverse consequences of fluoxetine-MAOI combination therapy. The Journal of clinical psychiatry, 1990, Volume: 51, Issue:6 Topics: Adult; Akathisia, Drug-Induced; Confusion; Depressive Disorder; Drug Interactions; Drug Therapy, Com	1990
Fluoxetine and stuttering. The Journal of clinical psychiatry, 1990, Volume: 51, Issue:7 Topics: Adult; Akathisia, Drug-Induced; Depressive Disorder; Diagnosis, Differential; Female; Fluoxetine; Hu	1990
Fluoxetine-induced akathisia in male OCD patients. The Journal of clinical psychiatry, 1990, Volume: 51, Issue:5 Topics: Akathisia, Drug-Induced; Female; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Sex Factor	1990
Fluoxetine-induced akathisia: clinical and theoretical implications. The Journal of clinical psychiatry, 1989, Volume: 50, Issue:9 Topics: Adolescent; Adult; Akathisia, Drug-Induced; Depressive Disorder; Dopamine; Dyskinesia, Drug-Induced;	1989
Toxic reaction following the combined administration of fluoxetine and L-tryptophan: five case reports. Biological psychiatry, 1986, Volume: 21, Issue:11 Topics: Adult; Akathisia, Drug-Induced; Arrhythmias, Cardiac; Drug Interactions; Female; Fluoxetine; Humans;	1986

fluoxetine and Acathisia, Drug-Induced